sapylin

Small moleculeexperimental

Clinical trial activity

6 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
2

Earliest trial started Apr 1, 2000 (NCT00010452)

Timeline

2000s

  1. Jan 1, 2000

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

  • Unspecified targetUnclear

    Unclear

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • ok432
  • ok432
  • ok-432
  • ok-432
  • picibanil
  • picibanil
  • sapylin
  • sapylin
  • sapylin
  • streptococcal preparation 722

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02502643N/AJul 1, 2015National Taiwan University
NCT02158299Phase 4Oct 1, 2013Guangzhou Medical University, Sun Yat-Sen University
NCT01699347Phase 4Sep 1, 2012University of Haifa
NCT01149902Phase 1Jul 1, 2010University of Yamanashi
NCT00795977Phase 1/Phase 2 (Phase 2)Nov 1, 2003Fukushima Medical University
NCT00010452Phase 2/Phase 3 (Phase 3)Apr 1, 2000University of Iowa
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Fukushima Medical UniversityAcademic/Hospital1112003
Guangzhou Medical UniversityAcademic/Hospital1012013
National Taiwan UniversityAcademic/Hospital1112015
Sun Yat-Sen UniversityAcademic/Hospital1112013
University of HaifaAcademic/Hospital1112012
University of IowaAcademic/Hospital1112000
University of YamanashiAcademic/Hospital1112010
7 organizations
Page 1 / 1